Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Partners (MOLN), Enliven Therapeutics (ELV...

Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enliven Therapeutics (ELVN), Molina Healthcare (MO...

Market Cap	$1.12B	P/E Ratio	N/A
52W High	$48.53	52W Low	$14.79
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	82.2%
Overall Score	51	Value Score	60
Quality Score	39	Technical Score	54

EPS Current Est	$-1.59	EPS Next Est	$-1.69
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$42.53	+2.38%	538.92K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$42.53	+2.4%	538.92K
3
4
5
6

ELVN

ELVN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel